Guidance statements: Hepatic Venous Pressure Gradient (HVPG) measurement is the gold-standard method to assess portal pressure in patients with cirrhosis.

This guidance provides a data-supported approach to risk stratification, diagnosis, and management of patients with cirrhosis and portal hypertension (PH).

16 сент. 2024 г. · The 2016 AASLD provides the following guidance for noninvasive testing for the diagnosis of clinically significant portal hypertension (CSPH).

There are no clear guidelines on HRS-CKD management due to a lack of literature. Diuretic therapy should be avoided in patients with functional renal ...

BCS is considered secondary when the mechanism for venous obstruction is an extrinsic compression, for example by a benign or malignant tumour.

AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis.

Manage portal hypertension! Page 9. Pharmacologic therapy for management of CSPH. Cochrane comparison: Carvedilol vs. other. NSBB for the outcome of HVPG.

Portal hypertension is assumed to be present when a patient with chronic liver disease has collateral circulation, splenomegaly, ascites, or portosystemic ...

The Baveno VII consensus workshop has provided several novel recommendations regarding the management of patients with clinically significant portal ...

16 сент. 2024 г. · Pharmacologic therapy for portal hypertension includes the use of beta-blockers, most commonly propranolol and nadolol.